Ascletis Partner Sagimet Doses First Patient in US Phase III Acne Trial of Denifanstat

• Ascletis Pharma's partner Sagimet dosed the first patient in its U.S. Phase III denifanstat acne trial, announced October 23, 2026.
• The AURORA trial targets approximately 800 patients with moderate to severe acne, including 450 adolescents aged 12 or older.
• AURORA is intended to support a potential U.S. application for marketing approval of denifanstat, also known as ASC40.
• Previously reported Chinese Phase III results showed greater treatment success versus placebo than sarecycline, doxycycline or clascoterone cream.
• Under an exclusive license from Sagimet, Ascletis holds development, manufacturing and commercialization rights to denifanstat in Greater China.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261023-12380622), on October 23, 2026, and is solely responsible for the information contained therein.